Enhancing the efficacy of innate immune agonists: Could nanolipoprotein particles hold the key?

Nanomedicine

Volumn 9, Issue 3, 2014, Pages 369-372

  Fischer, Nicholas O ^a   Blanchette, Craig ^a   Rasley, Amy ^a  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

Agonist; Immune modulation; Infectious disease; Innate immunity; Nanolipoprotein particles; Nanotechnology

Indexed keywords

NANOLIPOPROTEIN PARTICLE; NANOPARTICLE; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; LIPOPROTEIN;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; CANCER THERAPY; DIAGNOSTIC IMAGING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION RESISTANCE; INNATE IMMUNITY; LIPID BILAYER; MEDICAL DOCUMENTATION; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; CHEMISTRY; DRUG EFFECTS;

ADJUVANTS, IMMUNOLOGIC; DRUG CARRIERS; HUMANS; IMMUNITY, INNATE; LIPOPROTEINS; NANOPARTICLES;

EID: 84898998540     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.15     Document Type: Review

References (20)

1. Beutler B. Innate immunity: an overview. Mol. Immunol. 40(12), 845-859 (2004).
2. Weilhammer DR, Blanchette CD, Fischer NO et al. The use of nanolipoprotein particles to enhance the immunostimulatory properties of innate immune agonists against lethal influenza challenge. Biomaterials 34(38), 10305-10318 (2013).
3. Wong JP, Christopher ME, Viswanathan S et al. Antiviral role of Toll-like receptor-3 agonists against seasonal and avian influenza viruses. Curr. Pharm. Design 15(11), 1269-1274 (2009).
4. Norton EB, Clements JD, Voss TG, Cardenas-Freytag L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J. Virol. 84(6), 2983-2995 (2010).
5. Lembo A, Pelletier M, Iyer R et al. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J. Immunol. 180(11), 7574-7581 (2008).
6. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162(4), 2291-2298 (1999).
7. Jiang T, Zhao H, Li XF et al. CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic influenza virus infection in a murine model. Antiviral Res. 89(1), 124-126 (2011).
8. Judy BM, Taylor K, Deeraksa A et al. Prophylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosis. PLoS ONE 7(3), e34176 (2012).
9. Juffermans NP, Leemans JC, Florquin S et al. CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect. Immun. 70(1), 147-152 (2002).
10. Amlie-Lefond C, Paz DA, Connelly MP, Huffnagle GB, Whelan NT, Whelan HT. Innate immunity for biodefense: a strategy whose time has come. J. Allergy Clin. Immunol. 116(6), 1334-1342 (2005).
11. National Research Council. Treating Infectious Diseases in a Microbial World: Report of Two Workshops on Novel Antimicrobial Therapeutics. The National Academies Press, DC, USA (2006).
12. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430(6996), 257-263 (2004).
13. Lawton JA, Ghosh P. Novel therapeutic strategies based on toll-like receptor signaling. Curr. Opin. Chem. Biol. 7(4), 446-451 (2003).
14. Salata O. Applications of nanoparticles in biology and medicine. J. Nanobiotechnol. 2(1), 3 (2004).
15. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14(5), 1310-1316 (2008).
16. Schuler MA, Denisov IG, Sligar SG. Nanodiscs as a new tool to examine lipid-protein interactions. Methods Mol. Biol. 974, 415-433 (2013).
17. Fischer NO, Rasley A, Corzett M, Hwang MH, Hoeprich PD, Blanchette CD. Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens. J. Am. Chem. Soc. 135(6), 2044-2047 (2013).
18. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 6(10), 2220-2224 (2006).
19. Nelson KG, Bishop JV, Ryan RO, Titus R. Nanodiskassociated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice. Antimicrob. Agent. Chemother. 50(4), 1238-1244 (2006).
20. Burgess BL, He Y, Baker MM et al. NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency. Int. J. Nanomed. 8, 4733-4743 (2013).